-
iPSC Models of Schizophrenia and Bipolar Disorder
2026-08-26
This resource study established and characterized three human iPSC lines from two cousins diagnosed with schizophrenia or bipolar disorder and an unaffected cousin. The family-linked panel provides a practical platform for investigating neurodevelopmental mechanisms, although disease-specific phenotypes still require neural differentiation and functional validation.
-
RNA Pol II Loss Activates Apoptosis Beyond Transcription
2026-08-26
Harper et al. show that RNA polymerase II inhibition kills cells through active apoptotic signaling triggered by depletion of hypophosphorylated RNA Pol IIA, rather than through passive loss of transcriptional output. Their PDAR framework links RNA Pol II degradation to mitochondrial death signaling and offers a mechanistic lens for interpreting transcription-targeting drugs.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-08-25
FITC-Concanavalin A (ConA) Conjugate is a direct fluorescent probe for accessible α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids. It supports cell-surface carbohydrate detection, tissue imaging, and flow cytometry, but should not be used as a universal glycan stain or as a probe for non-carbohydrate targets.
-
Sodium Citrate for Smarter SERS Assay Design
2026-08-25
Explore how Sodium citrate can shape solution chemistry without being mistaken for the structural driver of 3D SERS performance. This evidence-led guide connects citrate buffering and chelation with polymer pen lithography, assay controls, and reproducibility decisions.
-
Phenytoin: Sodium Channels and Myelin Assays
2026-08-24
Phenytoin, also known as 5,5-diphenylimidazolidine-2,4-dione, is a research compound used to study voltage-gated sodium channel modulation and neuronal excitability. Recent work shows that neuronal activity can worsen early myelin swelling, but it does not establish phenytoin as a myelin-repair treatment.
-
Triacetin Workflows for Metabolic and Cell Assays
2026-08-24
Triacetin, or glyceryl triacetate, supports cell-based oncology studies, metabolic experiments, and ocular formulation screening as both a chemical perturbant and formulation component. This practical guide connects dose selection, vehicle controls, aerosol chemistry insights, and troubleshooting for more reproducible life science assays.
-
RRP Restores Lipid Metabolism in Liver Injury
2026-08-23
The reference study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by correcting hepatocyte cholesterol handling, rather than acting only as nonspecific antioxidants. Its mechanistic model connects AMPK–mTOR signaling with suppression of SCAP–SREBP2 cholesterol synthesis and activation of LXRα-dependent cholesterol efflux, providing a useful framework for lipid metabolism research.
-
Fulvestrant: ER Signaling Workflows and Use Cases
2026-08-22
Fulvestrant (ICI 182,780) combines high-affinity ER antagonism with ERα degradation, making it useful for mechanistic studies of endocrine therapy resistance, MDM2 turnover, and chemotherapy response. This workflow also shows how findings from immune and endoplasmic-reticulum-stress research can inform, but not replace, breast cancer assay design.
-
Testosterone Bounce in Degarelix-Treated Prostate Cancer
2026-08-22
This retrospective study identifies testosterone bounce, defined using a 20 ng/dL nadir and maximum threshold, as a prognostic marker for overall and cancer-specific survival in prostate cancer patients receiving degarelix. The findings support serial testosterone assessment as a complementary biomarker strategy, while the absence of a progression-free survival association and the retrospective design limit causal interpretation.
-
FGF4-FGFR1 Signaling Protects Podocytes in DKD
2026-08-21
This Nature Communications study identifies podocyte-secreted FGF4 as an endogenous protector of glomerular integrity in diabetic kidney disease. Genetic loss-of-function, recombinant FGF4 treatment, and human podocyte experiments support an FGFR1–AMPK–FOXO1 mechanism that limits oxidative stress and apoptosis, although translation beyond male mouse models remains to be established.
-
Leupeptin Hemisulfate: Translational Control
2026-08-20
Leupeptin hemisulfate salt is more than a broad protease inhibitor: it is a mechanistic tool for connecting protease activity regulation with protein degradation studies, viral replication inhibition, and autophagy interpretation. This thought-leadership perspective outlines how to use Leupeptin, Microbial strategically, while applying the direct-binding and functional-validation principles demonstrated in a recent TET2 metabolite-regulation protocol.
-
Streptavidin-FITC for LNP Trafficking Assays
2026-08-20
Streptavidin-FITC enables biotin-resolved fluorescence for studying nanoparticle uptake, endosomal trafficking, and biomolecular localization. This article translates recent LNP trafficking findings into practical assay-design decisions, controls, and interpretation limits.
-
Protease Inhibitor Cocktail: Workflow & Troubleshooting
2026-08-19
Learn how an EDTA-free, 100X formulation protects labile proteins, preserves phosphorylation-sensitive samples, and supports Western blot, immunoprecipitation, and enzyme workflows. Practical dilution guidance and troubleshooting steps help reduce degradation without compromising divalent-cation-dependent assays.
-
DMXAA (Vadimezan): Mechanism and Research Use
2026-08-19
DMXAA, also called Vadimezan, is a preclinical vascular disrupting agent with reported DT-diaphorase inhibition, VEGFR2-related signaling effects, and tumor endothelial apoptosis. Its research value also extends to STING agonist delivery in a 2024 nanorod study, but that nanomedicine evidence should not be generalized to unconjugated DMXAA.
-
Erlotinib and SCUBE3: A Translational EGFR Strategy
2026-08-18
Erlotinib offers a precise way to interrogate EGFR-dependent signaling while new SCUBE3 biology reframes tumor growth, therapy resistance, and immune suppression as interconnected processes. This thought-leadership guide translates that mechanism into practical assay design, biomarker strategy, and translational decision-making.